TransTech Pharma and SIGA Technologies, which is based in New York, will develop treatments for smallpox, monkeypox and other ailments under a $2.7 million grant from the National Institutes of Health.

The companies said they also are working on products as part of biowarfare defense.

“We are pleased to share in this award with TransTech as validation of our capabilities to advance these research programs to the next level,” said Dennis Hruby, chief scientific officer of SIGA.

The companies are conducting research utilizing protease inhibitors.